← Leaderboards
Jennifer Tang
Univ Of North Carolina Chapel Hill
$3,204,850
Attributed
$3,378,100
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $701K · FY2013–21$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$3,378,100 · 3
By mechanism
R01$2,466,256 · 1
K01$565,344 · 1
R21$346,500 · 1
Top collaborators
- Mina C Hosseinipour2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Soumya Rahima Benhabbour$11,411,217
- Samuel Lai$12,082,303
- Brooke Whitney Bullington$39,440
Others in their field
Top investigators on “Women&Apos”
- Steven T Dekosky · Rush University Medical Center$18,932,347
- Jose A Luchsinger · Columbia University Health Sciences$16,383,484
- Corette B Parker · Research Triangle Institute$14,403,014
- Kejal Kantarci · Mayo Clinic Rochester$8,220,660
- George R. Saade · Research Triangle Institute$7,301,796
- Philip Greenland · Research Triangle Institute$7,301,796
Research focus
Women&AposEnrollmentMalawiAfrica South Of The SaharaWomanCountryRecommendationPreventResearch DesignLevonorgestrelMedroxyprogesterone 17-AcetateNorth CarolinaContraceptive UsageAreaContraceptive MethodsCollaborationsContraceptive AgentsInjectableContraceptive EfficacyBenefits And RisksImplantDecision MakingFollow-UpMaternal Mortality
Grant awards (11)
A prospective cohort of HIV-infected Malawian women on Efavirenz initiating the Levonorgestrel Implant or the Depot Medroxyprogesterone Acetate Injectable$399,817
R01 · FY2021 · HD · contact PI
HIV viral suppression among women in Malawi before and after switch from efavirenz to dolutegravir: contextualizing viral outcomes with robust resistance and objective adherence measures$157,500
R21 · FY2021 · AI · contact PI
A prospective cohort of HIV-infected Malawian women on Efavirenz initiating the Levonorgestrel Implant or the Depot Medroxyprogesterone Acetate Injectable$511,970
R01 · FY2020 · HD · contact PI
HIV viral suppression among women in Malawi before and after switch from efavirenz to dolutegravir: contextualizing viral outcomes with robust resistance and objective adherence measures$189,000
R21 · FY2020 · AI · contact PI
A prospective cohort of HIV-infected Malawian women on Efavirenz initiating the Levonorgestrel Implant or the Depot Medroxyprogesterone Acetate Injectable$516,153
R01 · FY2019 · HD · contact PI
A prospective cohort of HIV-infected Malawian women on Efavirenz initiating the Levonorgestrel Implant or the Depot Medroxyprogesterone Acetate Injectable$515,417
R01 · FY2018 · HD · contact PI
A prospective cohort of HIV-infected Malawian women on Efavirenz initiating the Levonorgestrel Implant or the Depot Medroxyprogesterone Acetate Injectable$522,899
R01 · FY2016 · HD · contact PI
Evaluation of the immunologic and genital tract changes among Malawian women$141,336
K01 · FY2016 · TW · contact PI
Evaluation of the immunologic and genital tract changes among Malawian women$141,336
K01 · FY2015 · TW · contact PI
Evaluation of the immunologic and genital tract changes among Malawian women$141,336
K01 · FY2014 · TW · contact PI
Evaluation of the immunologic and genital tract changes among Malawian women$141,336
K01 · FY2013 · TW · contact PI